Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
CTD_human |
Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.
|
26901067 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.
|
26901067 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis revealed that the A variant of CDH1 -160C/A polymorphism was associated with an increased risk of bladder cancer.
|
24491043 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations.
|
24404589 |
2014 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
CDH1 and SFN genes were methylated at high frequencies in bladder cancer as well as in paired normal adjacent tissue and exfoliated cells from cancer-free patients.
|
18702824 |
2008 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
CTD_human |
Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma.
|
17520682 |
2007 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
[Use of silicon chip technology to detect protein-based tumor markers in bladder cancer].
|
17593336 |
2007 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to investigate the association of an E-cadherin promoter polymorphism (CDH1c-160a) with the risk of bladder cancer recurrence.
|
16922727 |
2006 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study supports earlier suggestions that the -160 C/A SNP in the CDH1 promoter is a risk factor for bladder cancer.
|
16934975 |
2006 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
RGD |
E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.
|
17167984 |
2006 |
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
LHGDN |
Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
|
11839665 |
2002 |
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
LHGDN |
Normal and bladder cancer samples from 51 patients were compared in terms of E-cadherin gene expression and methylation status by immunohistochemistry, methylation-specific polymerase chain reaction (MSP), and bisulfite genome-sequencing techniques.
|
12203370 |
2002 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Normal and bladder cancer samples from 51 patients were compared in terms of E-cadherin gene expression and methylation status by immunohistochemistry, methylation-specific polymerase chain reaction (MSP), and bisulfite genome-sequencing techniques.
|
12203370 |
2002 |
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
We investigated the possibility that aberrant methylation of the CpG island flanking the 5' transcriptional start site of the e-cadherin gene is responsible for the decreased expression of this gene in bladder cancer, similar to the relationship previously seen between e-cadherin methylation and gene expression in other types of human cancers.
|
11549575 |
2001 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These observations, which, nevertheless, need to be confirmed in a larger number of patients, suggest that alterations of E-cadherin gene may be related to pathobiology of bladder cancer development and clinical progression.
|
10891567 |
2000 |